Alkermes stock jumps on positive ADHD drug trial results

Alkermes' ALKS 7290, an orexin 2 receptor agonist, showed significant improvement in adult ADHD symptoms in a Phase 1B study. The drug reduced ADHD symptoms by 14-19 points and severity scores by 1-2 points. It was well-tolerated with mild side effects. Alkermes plans further trials, with results expected in 2027.

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

Alkermes reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. The company plans a Phase 2 study with 312 participants.

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

Alkermes' ALKS 7290 showed early efficacy in ADHD. J&J's Caplyta reduced bipolar mania symptoms. Novo Nordisk's CagriSema outperformed Lilly's tirzepatide in weight loss. Novo shares fell on investor day.